+

WO2003055979A3 - ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS - Google Patents

ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS

Info

Publication number
WO2003055979A3
WO2003055979A3 PCT/US2002/036496 US0236496W WO03055979A3 WO 2003055979 A3 WO2003055979 A3 WO 2003055979A3 US 0236496 W US0236496 W US 0236496W WO 03055979 A3 WO03055979 A3 WO 03055979A3
Authority
WO
WIPO (PCT)
Prior art keywords
blys
antibodies
immunospecifically bind
present
related molecules
Prior art date
Application number
PCT/US2002/036496
Other languages
French (fr)
Other versions
WO2003055979A2 (en
Inventor
Steven M Ruben
Steven C Barash
Gil H Choi
Tristan J Vaughan
David Hilbert
Original Assignee
Human Genome Sciences Inc
Steven M Ruben
Steven C Barash
Gil H Choi
Tristan J Vaughan
David Hilbert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Steven M Ruben, Steven C Barash, Gil H Choi, Tristan J Vaughan, David Hilbert filed Critical Human Genome Sciences Inc
Priority to EP02802570A priority Critical patent/EP1456347A4/en
Priority to CA002467521A priority patent/CA2467521A1/en
Priority to AU2002364954A priority patent/AU2002364954A1/en
Publication of WO2003055979A2 publication Critical patent/WO2003055979A2/en
Publication of WO2003055979A3 publication Critical patent/WO2003055979A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to antibodies and related molecules that immunospecifically bind to BlyS. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant BlyS expression or inappropriate function of BlyS comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to BlyS. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant BlyS expression or inappropriate BlyS function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to BlyS.
PCT/US2002/036496 2001-11-16 2002-11-14 ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS WO2003055979A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02802570A EP1456347A4 (en) 2001-11-16 2002-11-14 Antibodies that immunospecifically bind to blys
CA002467521A CA2467521A1 (en) 2001-11-16 2002-11-14 Antibodies that immunospecifically bind to blys
AU2002364954A AU2002364954A1 (en) 2001-11-16 2002-11-14 ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33146901P 2001-11-16 2001-11-16
US60/331,469 2001-11-16
US34081701P 2001-12-19 2001-12-19
US60/340,817 2001-12-19

Publications (2)

Publication Number Publication Date
WO2003055979A2 WO2003055979A2 (en) 2003-07-10
WO2003055979A3 true WO2003055979A3 (en) 2003-12-18

Family

ID=26987779

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036496 WO2003055979A2 (en) 2001-11-16 2002-11-14 ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS

Country Status (4)

Country Link
EP (1) EP1456347A4 (en)
AU (1) AU2002364954A1 (en)
CA (1) CA2467521A1 (en)
WO (1) WO2003055979A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592430B2 (en) 2003-09-10 2009-09-22 Amgen Fremont Antibodies to M-CSF
US12304943B2 (en) 2024-08-16 2025-05-20 Alpine Immune Sciences, Inc. April and BAFF inhibitory immunomodulatory proteins and methods of use thereof

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
EP1415659B9 (en) 1999-01-25 2012-02-15 Biogen Idec MA Inc. An antibody specific for soluble BAFF for use in the treatment of cancer
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
HU227947B1 (en) 1999-08-17 2012-06-28 Biogen Idec Inc Use of baff receptor (bcma) as an immunoregulatory agent
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
EP2275449B1 (en) 2000-06-16 2016-09-28 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
JP5524441B2 (en) 2003-03-28 2014-06-18 バイオジェン・アイデック・エムエイ・インコーポレイテッド Shortened BAFF receptor
ES2537738T3 (en) 2003-06-05 2015-06-11 Genentech, Inc. Combination therapy for B cell disorders
EP1664115A2 (en) * 2003-08-01 2006-06-07 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
CN101921338A (en) 2004-03-31 2010-12-22 佳能株式会社 Gold-binding protein and use thereof
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
WO2006025345A1 (en) * 2004-08-31 2006-03-09 Kowa Company, Ltd. Antihuman baff antibody
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
AU2008230777B8 (en) 2007-03-27 2014-07-03 Ares Trading S.A. Combination of BLyS and/or APRIL inhibition and immunosuppressants for treatment of autoimmune disease
TWI489993B (en) 2007-10-12 2015-07-01 Novartis Ag Compositions and methods of use for antibodies against sclerostin
EP2233149B1 (en) 2007-10-16 2016-02-10 ZymoGenetics, Inc. Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
CN103421113B (en) * 2012-05-22 2018-01-19 武汉华鑫康源生物医药有限公司 Anti- BLyS antibody
CN104045713B (en) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 The monoclonal antibody of anti-Blys a kind of and pharmaceutical composition containing the antibody
CN107586339B (en) * 2016-07-06 2023-01-20 尚华科创投资管理（江苏）有限公司 BLyS antibody and preparation method and application thereof
TWI716668B (en) 2017-02-01 2021-01-21 耶魯大學 Precision treatment of heart failure and cardiorenal syndrome
EA202091640A1 (en) 2018-01-05 2020-10-26 Корвидиа Терапьютикс, Инк. METHODS FOR TREATMENT OF IL-6-MEDIATED INFLAMMATION WITHOUT IMMUNODEPRESSION
CN116903727A (en) 2020-05-08 2023-10-20 高山免疫科学股份有限公司 APRIL and BAFF inhibitory immunomodulatory proteins with and without T cell inhibitory proteins and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087977A2 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
US20030012783A1 (en) * 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2048501A (en) * 2000-02-16 2001-08-27 Genentech Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
EP2275449B1 (en) * 2000-06-16 2016-09-28 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087977A2 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
US20030012783A1 (en) * 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1456347A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592430B2 (en) 2003-09-10 2009-09-22 Amgen Fremont Antibodies to M-CSF
US12304943B2 (en) 2024-08-16 2025-05-20 Alpine Immune Sciences, Inc. April and BAFF inhibitory immunomodulatory proteins and methods of use thereof

Also Published As

Publication number Publication date
EP1456347A4 (en) 2006-08-02
EP1456347A2 (en) 2004-09-15
WO2003055979A2 (en) 2003-07-10
AU2002364954A1 (en) 2003-07-15
AU2002364954A8 (en) 2003-07-15
CA2467521A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
WO2003055979A3 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
MXPA02012434A (en) Antibodies that immunospecifically bind to blys.
WO2002016411A3 (en) Binding polypeptides and methods based thereon
WO2003054216A3 (en) Antibodies that immunospecifically bind to trail receptors
DE60236646D1 (en) Anti-VEGF-2 antibodies
WO2002097033A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2002094192A3 (en) Antibodies against tumor necrosis factor delta (april)
BRPI0410129A (en) therapeutic use of anti-cs1 antibodies
WO2002083849A3 (en) Vascular endothelial growth factor 2
DE602004029399D1 (en)
BR0309095A (en) Use of osteoprotegerin for the treatment and / or prevention of fibrotic disease.
BR0209812A (en) Use of osteopontin for the treatment and / or prevention of neurological diseases.
BR0316723A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
BR0312768A (en) 5-Ariltetrazole compounds, compositions thereof and uses thereof
WO2003085093A3 (en) Antibodies that specifically bind to gmad
WO2005016236A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2004069183A3 (en) Immune regulation based on the targeting of early activation molecules
WO2004003144A3 (en) Antibodies that specifically bind to reg iv
BRPI0413404A (en) pharmaceutical compositions, methods of treating or preventing cardiac dysfunction, methods of enhancing cardiac function, and identifying mif inhibitor
WO2002079377A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2004016753A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2003042367A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2003086301A3 (en) Antibodies that specifically bind to tr2
BR0306869A (en) Orodispersibly pyribedyl pharmaceutical composition
WO2002070562A3 (en) Nuclear hormone receptor ligand binding domain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2467521

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002802570

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002802570

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载